GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
GeneDx Holdings Corp.NASDAQ: WGS
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin narrows to -15.5%
Net margin was -15.5% in Q2 FY2026, down 26.0 pp from a year earlier. On a trailing-twelve-month basis it was -23.4%, down 23.8 pp year over year. Over 3 fiscal years it widened by 229.0 pp.
Context
- Net margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 6 analysts of 2.2% for the fiscal year ending Dec 2026, up from -4.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -15.5%+46.4 pp QoQ
- Last fiscal yearDec 2025
- -4.9%+12.2 pp YoY
- LTMJun 2026
- -23.4%-23.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -26.0 pp | +8.3 pp | +34.3 pp |
| 1 year | +12.2 pp | +7.1 pp | -5.1 pp |
| 3 years | +229.0 pp | +13.8 pp | -215.2 pp |
| 5 years | +18.4 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4.9%
- Year-over-year change
- +12.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4.9% | +12.2pp |
| FY2024 | 2024-12-31 | -17.1% | +69.7pp |
| FY2023 | 2023-12-31 | -86.8% | +147.1pp |
| FY2022 | 2022-12-31 | -233.9% | -118.3pp |
| FY2021 | 2021-12-31 | -115.6% | — |
Net Margin vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's LTM Jun 2026 net margin of -23.4% is the 5th highest of the 9 companies compared; the peer median is -27.1%.
- Its year-over-year change of -23.8 pp is the 6th highest of 9, against a peer median of -5.7 pp.
- Over three fiscal years its change of +229.0 pp compares with a peer median of +27.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | 8.4% | +23.1 pp | — |
| LTM Mar 2026 | -3.8% | -2.3 pp | +42.0 pp | |
| LTM Jun 2026 | -6.8% | +8.3 pp | +13.4 pp | |
| LTM Mar 2026 | -23.0% | -9.1 pp | -41.9 pp | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -23.4% | -23.8 pp | +229.0 pp |
| FY2025 | -31.1% | +11.2 pp | +87.8 pp | |
| LTM Mar 2026 | -48.2% | -36.0 pp | -27.9 pp | |
| LTM Mar 2026 | -148.1% | -50.0 pp | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2454.6% | -940.1 pp | +6371.3 pp |
| Peer median (excluding WGS) | -27.1% | -5.7 pp | +27.7 pp | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 212.2M | 234.69M | 202.57M | 305.45M | 427.54M |
| Cost of Revenue | 228.8M | 261.44M | 112.56M | 111.05M | 129.37M |
| Gross Profit | (16.6M) | (26.75M) | 90.01M | 194.4M | 298.17M |
| Gross Margin | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% |
| Research & Development | 105.16M | 86.2M | 58.27M | 45.72M | 72.03M |
| Selling, General & Admin | 318.73M | 338.24M | 194.71M | 168.48M | 239.22M |
| Operating Expenses | 429.55M | 640.9M | 270.6M | 217.61M | 311.25M |
| Depreciation & Amortization | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| EBITDA | (220.75M) | (398.2M) | (136.46M) | (27.64M) | 6.63M |
| EBITDA Margin | -104.0% | -169.7% | -67.4% | -9.1% | 1.5% |
| Operating Income | (446.15M) | (667.65M) | (180.6M) | (23.21M) | (11.8M) |
| Operating Margin | -210.3% | -284.5% | -89.2% | -7.6% | -2.8% |
| Interest Income | 79K | 2.54M | 1.11M | 0 | 0 |
| Interest Expense | 2.84M | 3.21M | 0 | 3.03M | 2.54M |
| Other Income / Expenses | 200.76M | 69.62M | 3.9M | (29.42M) | (9.34M) |
| Income Before Tax | (245.39M) | (598.03M) | (176.69M) | (52.63M) | (21.14M) |
| Pre-Tax Margin | -115.6% | -254.8% | -87.2% | -17.2% | -4.9% |
| Income Tax Expense | 0 | (49.05M) | (926K) | (343K) | (116K) |
| Net Income | (245.39M) | (548.98M) | (175.77M) | (52.29M) | (21.02M) |
| Net Margin | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |
| EPS (Basic) | (74.93) | (53.63) | (7.23) | (1.94) | (0.73) |
| EPS (Diluted) | (74.93) | (53.63) | (7.23) | (1.94) | (0.73) |
| Weighted Avg Shares | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M |
| Weighted Avg Shares (Diluted) | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.